Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
35 hedge funds and large institutions have $23M invested in Cymabay Therapeutics in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 7 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
27% more capital invested
Capital invested by funds: $18.2M → $23M (+$4.81M)
21% more funds holding
Funds holding: 29 → 35 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$4.36M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$2.59M |
| 3 |
AC
Armistice Capital
New York
|
+$2.28M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.91M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$2.31M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.26M |
| 3 |
VAM
Visium Asset Management
New York
|
-$626K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$97K |
| 5 |
PP
PDT Partners
New York
|
-$75K |
CBAY Hedge Fund Activity: Q3 2015 in Review
35 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2015, worth a combined $23M — up 27% from $18.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CBAY positions and 7 closed out — a net gain of 6 holders — while 11 added to existing stakes and 2 trimmed.
The largest buyer was Abingworth, opening a new position worth an estimated $4.36M. The largest seller was Jennison Associates, exiting entirely with an estimated $2.31M sold.
- 35 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2015, up from 29 in Q2 2015.
- Funds reported $23M of Cymabay Therapeutics stock for Q3 2015, up 27% quarter-over-quarter.
- 13 funds opened new Cymabay Therapeutics positions in Q3 2015 and 7 closed out, a net change of +6 holders.
- The largest Cymabay Therapeutics buyer in Q3 2015 was Abingworth, an estimated $4.36M added.
- The largest Cymabay Therapeutics seller in Q3 2015 was Jennison Associates, an estimated $2.31M sold.
Based on aggregated 13F filings for Q3 2015.